세계의 간질 치료제 시장 : 간질 유형별, 약제별, 투여 경로별, 연령대별, 유통 채널별, 지역별

The epilepsy drugs market is estimated to be valued at USD 10.31 Bn in 2024 and is expected to reach USD 14.77 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

Figure. Epilepsy Drugs Market Share (%), By Region, 2024

Epilepsy is a chronic non-communicable disease characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body or the entire body. Its symptoms include abnormal electrical discharges in the brain causing seizures. It affects people of all ages but is more common in children and older adults. There is no cure for epilepsy but seizures can be controlled in about 70% of cases with medication. The global epilepsy drugs market is primarily driven by the increasing prevalence of epilepsy worldwide. Advancements in the treatment options with new drugs in the pipeline also support the growth of this market.

Market Dynamics

Global epilepsy drugs market growth is primarily driven by increasing prevalence of epilepsy worldwide. In 2022, it was estimated that over 50 million people have epilepsy globally according to the World Health Organization. The market also witnesses opportunities due to the rising healthcare expenditures across various countries. However, the market growth can be restrained by the expiry of patents of blockbuster drugs and price erosion faced by some generic drugs. The development of novel drugs for treatment-resistant epilepsy also presents growth opportunities in the market.

Key Features of the Study:

This report provides in-depth analysis of the global epilepsy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global epilepsy drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global epilepsy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epilepsy drugs market

Market Segmentation

• Type of Epilepsy Insights
  • Focal Epilepsy
  • Generalized Epilepsy
  • Reflex Epilepsy
  • Others (Progressive Myoclonic Epilepsy, etc.)
• Drugs Insights
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
• Route of Administration Insights
  • Oral
  • Injectable
  • Others (Nasal, etc.)
• Age Group Insights
  • Pediatric
  • Adults
  • Geriatric
• Distribution Channel Insights
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Novartis AG
  • Abbott
  • GSK plc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Marinus Pharmaceuticals, Inc
  • Eisai Co., Ltd
  • DAIICHI SANKYO COMPANY, LIMITED
  • Mylan N.V.
  • Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Neurelis, Inc.
  • Supernus Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Epilepsy Drugs Market, By Type of Epilepsy
  • Epilepsy Drugs Market, By Drugs
  • Epilepsy Drugs Market, By Route of Administration
  • Epilepsy Drugs Market, By Age Group
  • Epilepsy Drugs Market, By Distribution Channel
  • Epilepsy Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Epilepsy Drugs Market, Type of Epilepsy, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Focal Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Generalized Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Reflex Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others (Progressive Myoclonic Epilepsy, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Epilepsy Drugs Market, By Drugs, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• 1st Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 2nd Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 3rd Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Epilepsy Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others (Nasal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Epilepsy Drugs Market, By Age Group, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Epilepsy Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Epilepsy Drugs Market, By Region, 2019 - 2031, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  • South Africa
  • North Africa
  • Central Africa

10. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sumitomo Pharma Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Marinus Pharmaceuticals, Inc
• Eisai Co., Ltd
• DAIICHI SANKYO COMPANY, LIMITED
• Mylan N.V.
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Neurelis, Inc.
• Supernus Pharmaceuticals, Inc.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us